蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 6758|回复: 7
收起左侧

[申报注册] EU GMP 新的附录16开始实施

[复制链接]
药生
发表于 2016-4-6 21:57:48 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
GMP News
06/04/2016
Thenew Annex 16 is coming into Force
新的附录16开始实施
The new Annex 16 "Certification by a QualifiedPerson and Batch Release" will become effective as of 15 April 2016.
新的附录“QP认证和批放行”将自2016年4月15日起开始生效。
It is centrally pointed out that the main duty of aQualified Person (QP) is the certification of batches. In this context, the QPmust personally ensure that the responsibilities listed under Chapter 1.6 arefulfilled. Chapter 1.7 lists many other responsibilities to be guaranteed bythe QP. However the related activities can be delegated and the QP can rely onthe respective quality management systems. Yet, the "QP should haveon-going assurance that this reliance is well founded" (1.7). The 21responsibilites listed include amongst others:
其中指出QP的主要任务就是批认证。在此情况下,QP必须以个人名义确保已履行第1.6款中列出的职责。第1.7条中列出了许多由QP来保证的其它职责。但是,相关活动可以委托,QP可以依赖于相应的质量管理体系。但是,“QP应该一直确保此依赖性已经建立好了”(1.7)。列出的21项职责中包括以下:
  • The starting materials used comply with the requirements and the     supply chain is known and under control.
  • 所用的起始物料符合要求,其供应链已知且受控。
  • The necessary audits have been carried out and the audit reports are     available.
  • 必要的审计已实施,有审计报告。
  • The manufacturing processes and testing methods are validated and in     accordance with the marketing authorisation.
  • 生产工艺和测试方法经过验证,符合上市许可内容。
  • Changes have been assessed and completed accordingly.
  • 变更经过评估,并已相应完成。
In this context, it is important to mention that theAnnex clearly highlights that the overall responsibility (safety, quality andefficacy) for a medicinal product lies with the marketing authorization holder(MAH). "However, the QP is responsible for ensuring that each individualbatch has been manufactured and checked (…) in accordance with the requirementsof the marketing authorisation (MA) and with Good Manufacturing Practice(GMP)" (see general principles).
在此情况下,要重点提到的是附录清楚强调了对于一个药品,上市许可持有人(MAH)的总体职责(安全、质量和有效性)。“但是,QP负责确保每个批次均根据上市许可(MA)的要求进行生产和检查……,并符合GMP要求”(参见通则)。
In cases where the QP has to rely on the functioningQM system of another site, the QP must ensure that a documented review andpermission of audit reports by third parties is available.
如果QP不得不依赖于另一个工三年的QM体系起作用,则QP必须确保有书面审核,并经允许可获取第三方审计报告。
Another important section clarifies the role of the QPwith regard to deviations and includes a few elements from EMA's position paperon QP Discretion (published in February 2006 and updated in January 2008).Chapter 3 of the new Annex describes the "handling of unexpecteddeviations". A batch with an unexpected deviation concerning the manufacturingprocess may be certified if the result of a risk analysis performed shows that"the potential impact of the deviation on quality, safety or efficacy ofthe batch(es) concerned and conclusion that the impact is negligible." Incases where a deviation concerns specification defined in the marketingauthorisation as essential for the release (OOS; out of specification), the QPwill still have no scope left.
另一个重要的部分说明了QP在偏差方面的作用,在EMA关于QP处置权(2006年公布,2008年1月更新)的立场文章中包括了几个要素。新附录的第3章描述了“非预期偏差的处理”。当一个批次的生产工艺发生非预期偏差时,如果所进行的风险分析的结果显示“偏差对相关批次质量、安全或有效性有潜在影响,结论是影响可以忽略”,则可以认证放行。如果发生一个不符合上市许可中定义的对放行具有重要意义的质量标准偏差(OOS),则QP就不能任意行事了。
During the consultation phase, interest groups haveexpressed their concerns with regard to the sampling of imported products. Now,the new Annex 16 makes clear that "samples may either be taken afterarrival in the EU, or be taken at the manufacturing site in the third inaccordance with a technically justified approach which is documented within thecompany's quality system. (…) Any samples taken outside the EU should beshipped under equivalent transport conditions as the batch that theyrepresent."  
在征求意见阶段,利益相关团体已表达了其对于进口药品的取样方面的担心。现在,新的附录16明确说“样品可以在其到达欧盟之后取,也可以在第三国生产场所根据公司质量体系书面说明,经过技术论证的方法取样(……)。所有在欧盟境外所取样品均应在与其所代表的批产品相等同的运输条件下运输。”
Regarding any requirements on import, the new Annex 16 "Certification by a Qualified Person and BatchRelease" has been kept relatively short. Those requirementswill probably be set in the new Annex 21.
关于进口的要求,新的附录16保持相对较短。这些要求可能会在新的附录21里来设定。

回复

使用道具 举报

药士
发表于 2016-4-7 00:24:53 | 显示全部楼层
回复

使用道具 举报

发表于 2016-4-7 08:16:27 | 显示全部楼层
In cases where the QP has to rely on the functioningQM system of another site, the QP must ensure that a documented review andpermission of audit reports by third parties is available.
如果QP不得不依赖于另一个工三年的QM体系起作用,则QP必须确保有书面审核,并经允许可获取第三方审计报告。

谢谢分享,友情提醒一下,上段中的红色文字翻译错误,应是“工厂”,不是“工三年”
回复

使用道具 举报

大师
发表于 2016-4-7 08:50:43 | 显示全部楼层
谢谢楼主的分享
回复

使用道具 举报

药徒
发表于 2016-4-7 09:35:26 | 显示全部楼层
有没有电子版的
回复

使用道具 举报

药徒
发表于 2016-4-7 09:42:48 | 显示全部楼层
楼主有没有电子版原版,可不可以分享下?
回复

使用道具 举报

药生
 楼主| 发表于 2016-4-7 21:44:31 | 显示全部楼层
1092957692 发表于 2016-4-7 09:42
楼主有没有电子版原版,可不可以分享下?

之前发过,你找找看,或者是在我博客上
回复

使用道具 举报

药生
发表于 2016-4-8 13:05:27 | 显示全部楼层
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-2-13 02:29

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表